<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RENESE-R- polythiazide and reserpine tablet </strong><br>Pfizer Labs<br></p></div>
<h1>RENESE®-R<br>(polythiazide/reserpine)<br>Tablets</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="box_warning"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First">This fixed combination drug is not indicated for initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is not static, but must be reevaluated as conditions in each patient warrant.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">RENESE®-R tablets combine polythiazide and reserpine, two antihypertensive agents with
complementary properties. Each blue, scored tablet of RENESE-R provides:</p>
<p>Renese (polythiazide). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.0 mg</p>
<p>Reserpine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . .0.25 mg</p>
<p>RENESE (polythiazide) is a member of the benzothiazide (thiazide) family of diuretic/antihypertensive agents. It is designated chemically as 2H-1,2,4-Benzothiadiazine-7-sulfonamide,6-chloro-3,4-dihydro-2-methyl-3-[[2,2,2-trifluoroethyl)thio]methyl]-,1,1-dioxide with a molecular formula of C<span class="Sub">11</span>H<span class="Sub">13</span>ClF<span class="Sub">3</span>N<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">3 </span>and a molecular weight of 439.87.</p>
<p>Polythiazide is a white crystalline substance insoluble in water, but readily soluble in alkaline solution, and has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=B503FA5E-5726-426D-867C-E8FE59ED3EAD&amp;name=renese-r-image01.jpg"></div>
<p>Reserpine, one of the alkaloids of <span class="Italics">Rauwolfia serpentina</span>, has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=B503FA5E-5726-426D-867C-E8FE59ED3EAD&amp;name=renese-r-image02.jpg"></div>
<p>Reserpine – which is administered orally, is insoluble in water, very slightly soluble in ether, 
l g in about 1800 mL alcohol and about 6 mL chloroform, slightly soluble in benzene, freely soluble in acetic acid.</p>
<p>It has a molecular weight of 608.69 and its molecular formula is C<span class="Sub">33</span>H<span class="Sub">40</span>N<span class="Sub">2</span>O<span class="Sub">9</span>. Reserpine is chemically designated as Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3β,16β,17α,18β,20α)-. It is a white or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> buff to slightly yellowish crystalline powder that is insoluble in water.</p>
<p>Inert Ingredients: FD&amp;C Blue No. 1; dibasic calcium phosphate; lactose; magnesium stearate; polyethylene glycol; sodium lauryl sulfate; starch; vanillin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Polythiazide</h2>
<p class="First">Renese (polythiazide) alone has demonstrated clinical effectiveness in lowering elevated blood pressure in patients without visible <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> as well as in edematous hypertensive patients. Its mechanism of action results in an interference with the renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic potency. The mechanism whereby thiazides function in the control of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is unknown. Polythiazide is well absorbed following oral administration with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> beginning approximately 2 hours later. Peak human plasma concentrations occur about 5 hours after ingestion. Polythiazide is removed slowly thereafter with a plasma elimination half-life of approximately 27 hours. One-fifth of the drug is recovered unchanged in human urine; the remainder is cleared via feces and as metabolites. Animal studies indicate metabolism occurs by rupture of the thiadiazine ring and loss of the side chain.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Reserpine</h2>
<p class="First">Reserpine has several complementary actions of benefit to the hypertensive patient, including a calming effect and a slowing of the pulse rate.</p>
<p>Depletion of norepinephrine from tissue receptor sites is thought to be responsible for the decrease in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and subsequent <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> is usually associated with this effect.</p>
<p>The tranquilizing effect of reserpine is apparently due to serotonin and catecholamine depletion in the brain.</p>
<p>Sympathetic inhibition produced by reserpine also may result in vasodilation and increased cutaneous blood flow with resulting <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling of warmth</span>, or <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>. Increased parasympathomimetic activity may produce increased gastrointestinal motility, increased gastric acid secretion and <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>.</p>
<p>Reserpine is absorbed orally and is widely distributed in body tissues, especially adipose tissue. A study in a small number of normal subjects who received a radioactively labeled 0.25 mg dose of reserpine showed a biphasic half-life of 4.5 hours during the first phase, and 11.3 days during the second phase. The full therapeutic effects of reserpine may not be seen for 2–3 weeks. </p>
<p>Reserpine is extensively metabolized to inactive compounds. It is slowly excreted via the urine and feces.</p>
<p>Reserpine crosses the blood-brain barrier and the placenta, and appears in cord blood.</p>
<p>Since polythiazide reduces or eliminates the sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> frequently associated with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, it enhances the efficacy of reserpine in lowering elevated blood pressure. RENESE-R often has been found to be more effective than equivalent doses of either agent alone. Both the cardiovascular and central nervous system effects may persist following withdrawal of the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (see <a href="#box_warning">box warning</a>).</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-4.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as they are in the absence of pregnancy (however, see <a href="#Pregnancy_section">Precautions/Pregnancy</a> section). <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> – including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">A.   Related to polythiazide</p>
<ol>
<li>Advanced renal or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to this or other sulfonamide derivatives.</li>
</ol>
<p>B.   Related to reserpine</p>
<ol>
<li>Demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</li>
<li>Patients with a history of mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</li>
<li>Demonstrated <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Serum electrolyte determinations are especially indicated for patients with severe derangement of metabolic processes, e.g., surgery, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or parenteral fluid therapy. <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> may be caused by certain diseases such as cirrhosis, or it may result from drug therapy, such as therapy with corticosteroids. Patients with cirrhosis who are continually receiving RENESE-R  should be observed carefully for the development of hepatic <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">precoma</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Indications of impending <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> are <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and hepatic fetor.</p>
<p>Thiazides may precipitate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span> in patients with pre-existing renal pathology and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Available information tends to implicate all oral dosage forms of potassium salts ingested in solid form with or without thiazides in the etiology of nonspecific, small bowel lesions consisting of ulceration with or without stenosis, causing obstruction, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and perforation, and frequently requiring surgery. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to these complications have been reported. All oral dosage forms of potassium salts ingested in solid form should be used only when adequate dietary supplementation is not practical, and should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> occur. </p>
<p>RENESE-R does not itself contain enteric-coated potassium.</p>
<p>Electroshock therapy should not be given within one week of cessation of reserpine.</p>
<p>Reserpine may cause mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Recognition of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may be difficult because this condition may often be disguised by somatic complaints (Masked <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>). The drug should be discontinued at first signs of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> such as despondency, early morning <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, or self-deprecation. Drug-induced <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may persist for several months after drug withdrawal and may be severe enough to result in <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Polythiazide</h3>
<p class="First">Since all diuretic agents may reduce serum levels of sodium, chloride, and potassium – especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or when used concurrently with steroids – patients should be observed regularly for early signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, and serum electrolyte studies should be performed periodically. Warning signs of possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. In extreme cases, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may develop. Frequently, serum electrolyte levels do not correlate with signs or symptoms of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>. Unduly restricted salt intake as well as concurrent administration of digitalis may exaggerate metabolic effects of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. A favorable ratio of potassium to sodium excretion lessens the possibility of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. However, should this occur or be suspected, foods with a high potassium content (bananas, apricots, citrus fruits, prune juice, etc.) should be given. When necessary, oral potassium supplements may be administered. If other antihypertensive agents are used concurrently, lower than usual doses of RENESE-R and of the other agents should be considered.</p>
<p>The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3>Reserpine</h3>
<p class="First"> Since reserpine may increase gastric acid secretion, it should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. Extreme caution is needed in patients with a history of mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and reserpine should be discontinued at the first sign of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> have been encountered, particularly in psychiatric patients, and constitute an indication for withdrawal of the drug. Caution should be exercised when treating patients with impairment of renal function, as <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">lowered blood pressure</span> may result in further decompensation and embarrassment of function.</p>
<p>Discontinue the drug one to two weeks prior to elective surgery since an unexpected degree of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> have been reported in patients receiving anesthetic agents concurrently with reserpine, probably due to a reduced responsiveness to norepinephrine. For emergency surgical procedures vagal blocking agents may be given parenterally to prevent or reverse <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Reserpine may cause <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in some patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Since RENESE-R may increase urination, it is advisable to take it early during the day. If <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span> occurs, take the drug with food or milk.</p>
<p>Notify your physician if <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> occur as these may indicate the loss of too much potassium from your body.</p>
<p>A few people who take this medicine may be more sensitive to sunlight than they are normally. Avoid too much sun or use of a sunlamp until you see how you react.</p>
<p>RENESE-R may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Make sure you know how you react before driving, using machinery, or performing tasks that require alertness.</p>
<p>Notify your physician if changes in mood or sleep patterns occur. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> may occur when getting up from a sitting or lying position. Getting up slowly may help. Notify your physician if the problem worsens.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1"></a><p></p>
<h3>Polythiazide</h3>
<p class="First">Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may be more likely to develop during concomitant use of corticosteroids or ACTH. Diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may precipitate <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
<p>Thiazide drugs may augment the paralyzing actions of tubocurarine, and may decrease the arterial responsiveness to norepinephrine. Extra precautions may be necessary in patients who may require these drugs or their derivatives, as in surgery.</p>
<p>Dosage adjustment of antidiabetic agents is frequently indicated during thiazide administration. Indomethacin may partially antagonize the hypotensive effect of the thiazide diuretics. Generally, do not give lithium with diuretics because they reduce lithiums renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
<p>Quinidine, a weak base, may have its half-life prolonged by concomitant administration of thiazide diuretics which alkalinize the urine.</p>
<p>Sulfonamides may potentiate the action of the thiazide diuretics, possibly by displacement from binding sites on plasma albumin.</p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> may be aggravated by the use of alcohol, barbiturates, or narcotics with thiazide diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.2"></a><p></p>
<h3>Reserpine</h3>
<p class="First">Reserpine should be used cautiously with digitalis or quinidine as the concurrent use may enhance the appearance of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.</p>
<p>Additive CNS depressant effects may occur when reserpine is administered concomitantly with other CNS depressants such as barbiturates and alcohol.</p>
<p>Concomitant administration of reserpine and levodopa has been reported to reduce the patient's response to levodopa. Reserpine should be avoided in patients receiving levodopa.</p>
<p>The effects of indirect-acting sympathomimetic amines such as ephedrine may be decreased.</p>
<p>Patients who are receiving monoamine oxidase inhibitors may experience excitation and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> when reserpine is added. The combination should be avoided.</p>
<p>Reserpine may add to the pharmacologic effects of beta-adrenergic blocking agents (i.e., <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> and cardiovascular effects). </p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1"></a><p></p>
<h3>Polythiazide</h3>
<p class="First">The thiazides may alter various laboratory test results. These include all electrolytes, particularly potassium, BUN, glucose, and PBI. Thiazides may decrease serum PBI levels without signs of thyroid disturbance.</p>
<p>Like other thiazide diuretics, polythiazide may cause a rise in serum uric acid levels with or without overt symptoms of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.2"></a><p></p>
<h3>Reserpine</h3>
<p class="First">Chronic administration results in a decrease in urinary catecholamines and vanilmandelic acid excretion.</p>
<p>Interference with colorimetric assay procedures for the determination of urinary
17-hydroxycorticosteroids by the Glenn-Nelson technique and 17-ketosteroids by the Holtorff Koch modification of the Zimmerman reaction have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Animal Tumorigenicity</h2>
<p class="First">Although long-term studies in animals have not been conducted with RENESE-R, rodent studies have shown that reserpine is an animal tumorigen, causing an increased incidence of mammary fibroadenomas in female mice, <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> of the seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> in male mice, and malignant adrenal medullary tumors in male rats. These findings arose in 2 year studies in which the drug was administered in the feed at concentrations of 5 and 10 ppm—about 100 to 300 times the usual human dose. The breast neoplasms are thought to be related to reserpine's prolactin-elevating effect.</p>
<p>Several other prolactin-elevating drugs have also been associated with an increased incidence of mammary neoplasia in rodents.</p>
<p>The extent to which these findings indicate a risk to humans is uncertain. Tissue culture experiments show that about one-third of human breast tumors are prolactin-dependent <span class="Italics">in vitro</span>, a factor of considerable importance if the use of the drug is contemplated in a patient with previously detected breast cancer. The possibility of an increased risk of breast cancer in reserpine users has been studied extensively; however, no firm conclusion has emerged. Although a few epidemiologic studies have suggested a slightly increased risk (less than twofold in all studies except one) in women who have used reserpine, other studies of generally similar design have not confirmed this. Epidemiologic studies conducted using other drugs (neuroleptic agents) that, like reserpine, increase prolactin levels and therefore would be considered rodent mammary carcinogens, have not shown an association between chronic administration of the drug and human mammary tumorigenesis. While long-term clinical observation has not suggested such an association, the available evidence is considered too limited to be conclusive at this time. An association of reserpine intake with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or tumors of the seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> has not been explored. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy_section"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with RENESE-R. There are no adequate and well controlled studies in pregnant women. It is also not known whether RENESE-R can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RENESE-R should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.7.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Thiazides cross the placental barrier and appear in cord blood. When polythiazide and reserpine are used in women of childbearing age, the potential benefits of this drug combination should be weighed against the possible hazards to the fetus. The hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possible other adverse reactions which have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Thiazides and reserpine appear in breast milk. Because of the potential for serious adverse reactions in nursing infants from RENESE-R, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been observed, but there is not enough systemic collection of data to support an estimate of their frequency.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Polythiazide</h2>
<p class="First">The most common reactions associated with polythiazide therapy are <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, but seldom require cessation of therapy. <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> is reported in less than 3% of patients receiving the drug, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> is reported in less than 2% of patients. These can be overcome by reducing the dose or taking measures to improve electrolytic balance.</p>
<p>Other reactions, reported to occur in less than 1% of patients, are:</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, reversible <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Italics">Dermatological:</span> maculopapular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
<p><span class="Italics">EENT:</span> <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
<p><span class="Italics">Hematological:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported with the older thiazides but not with the newer compounds such as polythiazide. <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span> (with or without <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) has been reported with polythiazide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Reserpine</h2>
<p class="First">The most common reactions associated with reserpine therapy, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, are reported in less than 2% of patients. Reactions to reserpine are usually reversible and disappear when the drug is discontinued.</p>
<p>Other reactions, occurring in less than 1% of patients on reserpine are:</p>
<p><span class="Italics">Gastrointestinal:</span> hypersecretion, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, paradoxical <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and rare Parkinsonian syndrome to CNS sensitization manifested by <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, and <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>.</p>
<p><span class="Italics">Cardiovascular:</span> angina-like symptoms, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>  particularly when used concurrently with digitalis or quinidine, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the skin, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Italics">EENT:</span> <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>.</p>
<p><span class="Italics">Sexual Difficulties:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> or decreased libido.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">One case of RENESE-R overdosage is reported after ingestion of an unknown number of tablets. Electrolyte replacement therapy was successful in treating the symptoms.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Polythiazide</h2>
<p class="First">An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Renese may cause <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, manifested by <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and/or other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Should overdosage with Renese occur, electrolyte balance and adequate hydration should be maintained. Gastric lavage is recommended followed by supportive treatment. Where necessary, this may include intravenous dextrose and saline with potassium and other electrolyte therapy, administered with caution as indicated by laboratory testing at appropriate intervals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Reserpine</h2>
<p class="First">Signs of overdosage include <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, skin <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, and extrapyramidal signs such as <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> or gastric lavage to remove unabsorbed drug is of benefit in conscious patients, even if several hours have elapsed since ingestion. Treatment is symptomatic and supportive.</p>
<p>Parasympathomimetic side effects usually can be controlled with small doses of atropine or other anticholinergics. Evidence of <span class="product-label-link" type="condition" conceptid="4203631" conceptname="Motor dysfunction">motor dysfunction</span> often can be controlled by drugs useful for <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>. Avoid vasopressor drugs (except in cases of extreme <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) and rapid intravenous infusions because of the uncertain cardiac status.</p>
<p>It is not known whether dialysis would be of benefit in treating cases of overdosage of RENESE-R.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">As determined by individual titration (see <a href="#box_warning">box warning</a>).</p>
<p>Initial dosages of the combination should conform to those dosages of the individual components established during titration.</p>
<p>Maintenance dosages range from ½ tablet to 2 tablets daily. Dosage of other antihypertensive agents, particularly ganglionic blockers, that are used concomitantly should be reduced.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">RENESE-R tablets (2 mg polythiazide–0.25 mg reserpine) are available as blue scored tablets, </p>tablet code 446, in bottles of 100 (NDC 0069-4460 -66) and 1,000 <br><p>(NDC-0069-4460-82). RENESE-R should be stored at room temperature. Dispense in tight, <br>light-resistant container.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Distributed by:</p>
<p>Pfizer Labs</p>
<p>Division of Pfizer, Inc, NY, NY 10017</p>
<p>69-1200-00-3</p>
<p>September 1995</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RENESE-R 		
					</strong><br><span class="contentTableReg">polythiazide and reserpine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4460</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>polythiazide</strong> (polythiazide) </td>
<td class="formItem"></td>
<td class="formItem">2 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>reserpine</strong> (reserpine) </td>
<td class="formItem"></td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>dibasic calcium phosphate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong> polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>vanillin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PFIZER;446</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4460-66</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0069-4460-82</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Labs</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6C732EA7-0BA6-D980-CCC0-E5045B674863</div>
<div>Set id: B503FA5E-5726-426D-867C-E8FE59ED3EAD</div>
<div>Version: 2</div>
<div>Effective Time: 20060206</div>
</div>
</div> <div class="DistributorName">Pfizer Labs</div></p>
</body></html>
